261 related articles for article (PubMed ID: 25069840)
1. Progesterone and estradiol synergistically promote the lung metastasis of tuberin-deficient cells in a preclinical model of lymphangioleiomyomatosis.
Sun Y; Zhang E; Lao T; Pereira AM; Li C; Xiong L; Morrison T; Haley KJ; Zhou X; Yu JJ
Horm Cancer; 2014 Oct; 5(5):284-98. PubMed ID: 25069840
[TBL] [Abstract][Full Text] [Related]
2. Estradiol promotes pentose phosphate pathway addiction and cell survival via reactivation of Akt in mTORC1 hyperactive cells.
Sun Y; Gu X; Zhang E; Park MA; Pereira AM; Wang S; Morrison T; Li C; Blenis J; Gerbaudo VH; Henske EP; Yu JJ
Cell Death Dis; 2014 May; 5(5):e1231. PubMed ID: 24832603
[TBL] [Abstract][Full Text] [Related]
3. Faslodex inhibits estradiol-induced extracellular matrix dynamics and lung metastasis in a model of lymphangioleiomyomatosis.
Li C; Zhou X; Sun Y; Zhang E; Mancini JD; Parkhitko A; Morrison TA; Silverman EK; Henske EP; Yu JJ
Am J Respir Cell Mol Biol; 2013 Jul; 49(1):135-42. PubMed ID: 23526212
[TBL] [Abstract][Full Text] [Related]
4. Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling.
Atochina-Vasserman EN; Goncharov DA; Volgina AV; Milavec M; James ML; Krymskaya VP
Am J Respir Cell Mol Biol; 2013 Nov; 49(5):704-9. PubMed ID: 23947572
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
[TBL] [Abstract][Full Text] [Related]
6. Estrogen maintains myometrial tumors in a lymphangioleiomyomatosis model.
Prizant H; Taya M; Lerman I; Light A; Sen A; Mitra S; Foster TH; Hammes SR
Endocr Relat Cancer; 2016 Apr; 23(4):265-80. PubMed ID: 26880751
[TBL] [Abstract][Full Text] [Related]
7. Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells.
Li C; Lee PS; Sun Y; Gu X; Zhang E; Guo Y; Wu CL; Auricchio N; Priolo C; Li J; Csibi A; Parkhitko A; Morrison T; Planaguma A; Kazani S; Israel E; Xu KF; Henske EP; Blenis J; Levy BD; Kwiatkowski D; Yu JJ
J Exp Med; 2014 Jan; 211(1):15-28. PubMed ID: 24395886
[TBL] [Abstract][Full Text] [Related]
8. Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation.
Goncharova EA; Goncharov DA; Chisolm A; Spaits MS; Lim PN; Cesarone G; Khavin I; Tliba O; Amrani Y; Panettieri RA; Krymskaya VP
Mol Pharmacol; 2008 Mar; 73(3):778-88. PubMed ID: 18094073
[TBL] [Abstract][Full Text] [Related]
9. Glutaredoxin-1 promotes lymphangioleiomyomatosis progression through inhibiting Bim-mediated apoptosis via COX2/PGE2/ERK pathway.
Feng Y; Li T; Li Y; Lin Z; Han X; Pei X; Zhang Y; Li F; Yang J; Shao D; Li C
Clin Transl Med; 2023 Jul; 13(7):e1333. PubMed ID: 37478294
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic effects of urotensin-II in cells lacking tuberous sclerosis complex-2.
Goldberg AA; Joung KB; Mansuri A; Kang Y; Echavarria R; Nikolajev L; Sun Y; Yu JJ; Laporte SA; Schwertani A; Kristof AS
Oncotarget; 2016 Sep; 7(38):61152-61165. PubMed ID: 27458154
[TBL] [Abstract][Full Text] [Related]
11. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
[TBL] [Abstract][Full Text] [Related]
12. Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.
Sun Y; Gallacchi D; Zhang EY; Reynolds SB; Robinson L; Malinowska IA; Chiou TT; Pereira AM; Li C; Kwiatkowski DJ; Lee PS; Yu JJ
Am J Respir Cell Mol Biol; 2014 Dec; 51(6):738-49. PubMed ID: 24874429
[TBL] [Abstract][Full Text] [Related]
13. Surfactant dysfunction and lung inflammation in the female mouse model of lymphangioleiomyomatosis.
Atochina-Vasserman EN; Guo CJ; Abramova E; Golden TN; Sims M; James ML; Beers MF; Gow AJ; Krymskaya VP
Am J Respir Cell Mol Biol; 2015 Jul; 53(1):96-104. PubMed ID: 25474372
[TBL] [Abstract][Full Text] [Related]
14. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM).
Goncharova EA; Goncharov DA; Eszterhas A; Hunter DS; Glassberg MK; Yeung RS; Walker CL; Noonan D; Kwiatkowski DJ; Chou MM; Panettieri RA; Krymskaya VP
J Biol Chem; 2002 Aug; 277(34):30958-67. PubMed ID: 12045200
[TBL] [Abstract][Full Text] [Related]
15. Estrogen activates pyruvate kinase M2 and increases the growth of TSC2-deficient cells.
Lu Y; Liu X; Zhang E; Kopras EJ; Smith EP; Astreinidis A; Li C; Leung YK; Ho SM; Yu JJ
PLoS One; 2020; 15(2):e0228894. PubMed ID: 32078667
[TBL] [Abstract][Full Text] [Related]
16. TSC2 epigenetic defect in primary LAM cells. Evidence of an anchorage-independent survival.
Lesma E; Ancona S; Sirchia SM; Orpianesi E; Grande V; Colapietro P; Chiaramonte E; Di Giulio AM; Gorio A
J Cell Mol Med; 2014 May; 18(5):766-79. PubMed ID: 24606538
[TBL] [Abstract][Full Text] [Related]
17. Effects of combining rapamycin and resveratrol on apoptosis and growth of TSC2-deficient xenograft tumors.
Alayev A; Salamon RS; Sun Y; Schwartz NS; Li C; Yu JJ; Holz MK
Am J Respir Cell Mol Biol; 2015 Nov; 53(5):637-46. PubMed ID: 25844891
[TBL] [Abstract][Full Text] [Related]
18. TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis.
Pacheco-Rodriguez G; Steagall WK; Crooks DM; Stevens LA; Hashimoto H; Li S; Wang JA; Darling TN; Moss J
Cancer Res; 2007 Nov; 67(21):10573-81. PubMed ID: 17975002
[TBL] [Abstract][Full Text] [Related]
19. Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis.
Makovski V; Haklai R; Kloog Y
Int J Cancer; 2012 Mar; 130(6):1420-9. PubMed ID: 21500191
[TBL] [Abstract][Full Text] [Related]
20. Lymphangioleiomyomatosis: A Monogenic Model of Malignancy.
Krymskaya VP; McCormack FX
Annu Rev Med; 2017 Jan; 68():69-83. PubMed ID: 28099079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]